IN VIVO EVALUATION OF ULTRASOUND ENHANCED LYSIS

Information

  • Research Project
  • 2647453
  • ApplicationId
    2647453
  • Core Project Number
    R44HL057739
  • Full Project Number
    2R44HL057739-02
  • Serial Number
    57739
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1998 - 26 years ago
  • Project End Date
    5/31/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    6/1/1998 - 26 years ago
  • Budget End Date
    5/31/1999 - 25 years ago
  • Fiscal Year
    1998
  • Support Year
    2
  • Suffix
  • Award Notice Date
    5/26/1998 - 26 years ago
Organizations

IN VIVO EVALUATION OF ULTRASOUND ENHANCED LYSIS

DESCRIPTION (Adapted from Applicant's Abstract): An estimated two million people a year are affected by arterial and venous thrombosis. Treatment with thrombolytic drugs is effective, but current procedures are only successful in dissolving thrombi in 70% to 80% of the patients. EKOS has developed an ultrasound catheter device and demonstrated an enhanced thrombolytic effect in-vitro and in vivo. The ultrasound transducer design and the associated acoustic parameters have been improved and early in vivo results indicate that ultrasound facilitated thrombolysis is as effective or better than the current standard-of-care pulse-spray type of devices for delivery of thrombolytic agents. The specific aims are: 1. Continue study of acoustic mechanisms. Specific tasks include: 1) study the role of microbubbles in enhancing thrombolysis with ultrasound; 2) examine the effect of various source pulsing conditions; and 3) develop an in-vitro blood clot model which simulates flow conditions in a partially occluded blood vessel. 2. In an animal model that simulates arterial thrombus occlusion, compare the safety and efficacy of the ultrasound infusion catheter with a conventional intravascular pulse-spray type infusion catheter. 3. Conduct a 10-patient pilot trial of peripheral arterial thrombolysis using the EKOS device and use the results to plan and initiate a prospective, multi-center study of 40 patients. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    EKOS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98011
  • Organization District
    UNITED STATES